首页|同步放化疗联合免疫治疗对局部晚期宫颈癌患者不良反应及效果的影响

同步放化疗联合免疫治疗对局部晚期宫颈癌患者不良反应及效果的影响

扫码查看
目的 探讨同步放化疗联合免疫治疗对局部晚期宫颈癌患者不良反应及效果的影响.方法 非随机选取2020年1月—2023年8月在德州市第二人民医院接受治疗的96例局部晚期宫颈癌患者为研究对象,根据治疗方法不同分成两组,各48例,对照组应用同步放化疗,研究组联合应用同步放化疗、免疫治疗.对比两组疾病控制率、血清肿瘤标志物、癌因性疼痛评分、癌因性疲乏评分、生活质量评分、不良反应发生率.结果 研究组疾病控制率为87.50%(42/48),高于对照组的68.75%(33/48),差异有统计学意义(χ2=4.937,P<0.05).治疗后,研究组中血清癌胚抗原、糖类抗原125、鳞状细胞抗原的水平均较对照组更低,研究组对癌因性疼痛、癌因性疲乏测评的分数均较对照组分数更低,研究组关于生活质量测评的四项分数均较对照组更高,差异有统计学意义(P均<0.05).两组不良反应发生率对比,差异无统计学意义(P>0.05).结论 在局部晚期宫颈癌患者同步放化疗治疗的同时,联合应用免疫治疗,可增强患者的近期疗效,控制肿瘤进展,减轻癌因性症状,有利于提高其生活质量水平,且不良反应未增多,安全性可靠.
Effect of Concurrent Chemoradiotherapy Combined with Immunotherapy on Adverse Reactions and Effects of Locally Advanced Cervical Cancer Pa-tients
Objective To explore the effect of concurrent chemoradiotherapy combined with immunotherapy on the ad-verse reactions and effects of locally advanced cervical cancer patients.Methods A total of ninety-six patients with lo-cally advanced cervical cancer who received treatment in the Second People's Hospital of Dezhou City from January 2020 to August 2023 were non-randomly selected as the study objects.They were divided into two groups according to different treatment methods,forty-eight cases in each group.The control group received simultaneous chemoradio-therapy,while the study group combined with simultaneous chemoradiotherapy and immunotherapy.Disease control rate,serum tumor markers,cancer-related pain score,cancer-related fatigue score,quality of life score and incidence of adverse reactions were compared between the two groups.Results The disease control rate of the study group was 87.50% (42/48),higher than 68.75%(33/48)of the control group,the difference was statistically significant(χ2=4.937,P<0.05).After treatment,the serum levels of carcinoembryonic antigen,carbohydrate antigen 125 and squamous cell antigen in the study group were lower than those in the control group,the scores of cancer-related pain and cancer-related fatigue in the study group were lower than those in the control group,and the scores of four aspects of quality of life in the study group were higher than those in the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Concurrent radiotherapy and chemotherapy combined with immunotherapy can enhance the short-term curative effect of patients with locally advanced cervical cancer,control tumor progression,alleviate cancer-related symptoms,and improve their quality of life,with no increase in adverse reactions,which is safe and reliable.

Locally advanced cervical cancerConcurrent radiotherapy and chemotherapyImmunotherapy

张雁亭、曲晨慧、赵楠

展开 >

德州市第二人民医院放疗科,山东 德州 253000

局部晚期宫颈癌 同步放化疗 免疫治疗

2024

系统医学

系统医学

ISSN:
年,卷(期):2024.9(17)
  • 11